Tuesday, November 4, 2008

OncoMed Gets $94M

Redwood City-based OncoMed Pharmaceuticals, which is developing antibudy therapeutics for the treatment of cancer, said Tuesday that it has raise $93M in a final tranche of its Series B financing round. According to the firm, the round brings its total Series B to $154M. The round was led by Nomura Phase4 Ventures. Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4, joins the firm's board as part of the funding. The firm's existing investors also participated, and include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures, Bay Partners, and GlaxoSmithKline. More information »